Stockscreener 앱 받기
1.34
0.00%
0.00
시간 외 거래:
1.34
전일 마감가:
$1.34
열려 있는:
$1.33
하루 거래량:
63,405
Relative Volume:
0.39
시가총액:
$6.42M
수익:
$19.53M
순이익/손실:
$-3.18M
주가수익비율:
-0.7097
EPS:
-1.888
순현금흐름:
$-4.13M
1주 성능:
+1.52%
1개월 성능:
+17.54%
6개월 성능:
-52.82%
1년 성능:
-73.67%
1일 변동 폭
$1.32
$1.35
1주일 범위
$1.29
$1.40
52주 변동 폭
$0.8501
$5.04
소노마 파머 Stock (SNOA) Company Profile
명칭
Sonoma Pharmaceuticals Inc
전화
800-759-9305
주소
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Compare SNOA vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
1.34 | 6.42M | 19.53M | -3.18M | -4.13M | -1.888 |
TAK
Takeda Pharmaceutical Co Adr
|
18.24 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.16 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.93 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.17 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
512.88 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
소노마 파머 주식(SNOA)의 최신 뉴스
Form 8K Sonoma Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Nigeria
Sonoma Pharmaceuticals cancels special meeting due to lack of quorum By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting - TipRanks
Sonoma Pharmaceuticals cancels special meeting due to lack of quorum - Investing.com
Price to earnings forward of Sonoma Pharmaceuticals, Inc. – SWB:O8Z - TradingView
Sonoma Pharmaceuticals reports 60% revenue growth in Q1 By Investing.com - Investing.com Nigeria
Sonoma Pharmaceuticals reports 60% revenue growth in Q1 - Investing.com
Sonoma FY2027 Q1 earnings: 60% revenue growth moves EBITDA positive - TradingKey
Sonoma Pharmaceuticals Q1 revenue rises on US growth - TradingView
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA - Bay to Bay News
BRIEF-Sonoma Pharmaceuticals Q1 Operating Expenses USD 2.6 Million - TradingView
Sonoma U.S. Revenue Climbs 141%; First-Ever Positive Adjusted EBITDA - Stock Titan
Sonoma Pharmaceuticals, Inc. Q1 2027: Revenue $6.41M, EPS $(0.09) — 10-Q Summary - TradingView
Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue - TradingView
Sonoma Pharmaceuticals (SNOA) Slides 5.83% to $1.13 as Key Support Level LoomsStop Loss Guidance - dars.gov.et
SNOA Q1'26 Earnings: EPS estimate is (0.30) USD - TradingView
SNOA Q2 2026 Earnings: Narrow EPS Miss Weighs on SharesROE Trend Analysis - Vinanet
Form DEF 14A SONOMA PHARMACEUTICALS For: 29 July By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals (SNOA) Hovers Near Support as Slight Decline ContinuesRVOL Breakout - vinanet.vn
Sonoma Pharmaceuticals Inc (SNOA) Institutional Confidence - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sonoma Pharmaceuticals Inc - TradingKey
SNOA|Sonoma Pharmaceuticals Inc|Price:1.140|Chg%:-0.020 - TradingKey
Sonoma Pharmaceuticals (SNOA) Slides 1.72% as Stock Holds Above Key Support at $1.08Negative Gamma - vinanet.vn
TradingKey - TradingKey
SNOA Q2 2026 Earnings: Slight EPS Miss, Stock Edges LowerProfit Warning Alert - vinanet.vn
SNOA Q2 2026 Earnings: EPS Misses Estimates; Stock Rises Amid Operational UpdatesCFO Commentary Report - Vinanet
19,898 Common Stock of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 24-JUL-2026. - marketscreener.com
Sonoma Pharmaceuticals (SNOA) Edges Higher as Volume Patterns Suggest Accumulation Near Key SupportAAII Bearish - dars.gov.et
Sonoma Pharmaceuticals (SNOA) Slips 4.21% as Stock Tests Key Support LevelsVWAP Bounce - vinanet.vn
Sonoma Pharmaceuticals (SNOA) Holds Steady at $1.26 as Consolidation ContinuesInside Day Breakout - dars.gov.et
Enterprise value to revenue forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Price to sales forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Sonoma Pharmaceuticals (NASDAQ: SNOA) awards CEO 10,000 RSUs in equity grant - Stock Titan
Enterprise value to EBIT forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Price to book forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView
Price to sales forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView
SNOA Should I Buy - Intellectia AI
Sonoma Pharmaceuticals (SNOA) Secures FDA Clearance for Microdac - GuruFocus
Sonoma Pharmaceuticals receives FDA clearance for wound solution - Investing.com
Sonoma Pharmaceuticals receives FDA clearance for wound solution By Investing.com - Investing.com Canada
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution - ACCESS Newswire
Sonoma Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SNOA) - TradingView
Sonoma Pharmaceuticals Inc (SNOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SNOA Q1 2026 Earnings: EPS Misses Estimates by 1.2%, No Revenue Reported, Stock Edges Up 0.87% - po-news-eg.net
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity - The Globe and Mail
Sonoma Pharmaceuticals Files 8-K for $3.6 Million Common Stock Offering – Nasdaq: SNOA, June 2026 - Minichart
According to a recent filing submitted to the U.S. Securities and Exchange Commission (SEC), Sonoma Pharmaceuticals, Inc. has raised the maximum total offering price of its common stock issuance to $3.64 million. - Bitget
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million - Investing.com UK
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million By Investing.com - Investing.com Nigeria
소노마 파머 (SNOA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.05%
자본화:
|
볼륨(24시간):